Regentis Biomaterials Completes $6.5 Million Private Placement

Regentis Biomaterials "announced that it has entered into definitive securities purchase agreements with accredited and institutional investors for the issuance and sale of ordinary shares (or pre-funded warrants in lieu thereof) together with warrants , at a purchase price of $3.50 per ordinary share and accompanying ordinary warrant (or $3.4999 per pre-funded warrant and accompanying ordinary warrant), in a private placement, for expected aggregate gross proceeds of approximately $6.5 million, before deducting placement agent fees and estimated offering expenses payable by us. The Company intends to use the net proceeds from the private placement to support continued execution of its pivotal clinical trial for GelrinC and to advance preparation of the pre-market approval submission to the Food and Drug Administration; to advance its Gelrin technology platform as well as product optimization; to support operational readiness, including manufacturing scale-up, regulatory affairs, and intellectual property protection; to support European market entry activities, including Medical Device Regulation compliance, marketing activities and related scale-up efforts and for working capital and general corporate purposes. ThinkEquity is acting as the exclusive placement agent in connection with the private placement."